Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
NEW YORK--(BUSINESS WIRE)--Laxxon - Veru Announcement
Could this development trigger any changes in short‑selling activity or institutional positioning in VERU?
What is the anticipated impact on VERU's cash burn and financing needs given the upcoming clinical and regulatory expenses?
How could this milestone influence analyst coverage and consensus estimates for VERU?
Symbol:
VERU
11 days ago